BAIRD MEDICAL INVESTMENT HOL (BDMD) Fundamental Analysis & Valuation
NASDAQ:BDMD • KYG0705H1039
Current stock price
1.79 USD
+0.07 (+4.07%)
Last:
This BDMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BDMD Profitability Analysis
1.1 Basic Checks
- BDMD had positive earnings in the past year.
- BDMD had a negative operating cash flow in the past year.
- In multiple years BDMD reported negative net income over the last 5 years.
- In the past 5 years BDMD always reported negative operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 16.24%, BDMD belongs to the top of the industry, outperforming 95.19% of the companies in the same industry.
- BDMD has a better Return On Equity (35.14%) than 97.86% of its industry peers.
- BDMD's Return On Invested Capital of 24.25% is amongst the best of the industry. BDMD outperforms 98.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.24% | ||
| ROE | 35.14% | ||
| ROIC | 24.25% |
ROA(3y)11.63%
ROA(5y)N/A
ROE(3y)20.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- BDMD has a Profit Margin of 33.76%. This is amongst the best in the industry. BDMD outperforms 99.47% of its industry peers.
- The Operating Margin of BDMD (41.35%) is better than 100.00% of its industry peers.
- Looking at the Gross Margin, with a value of 88.17%, BDMD belongs to the top of the industry, outperforming 96.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 41.35% | ||
| PM (TTM) | 33.76% | ||
| GM | 88.17% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. BDMD Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BDMD is creating value.
- The number of shares outstanding for BDMD has been reduced compared to 1 year ago.
- The debt/assets ratio for BDMD is higher compared to a year ago.
2.2 Solvency
- An Altman-Z score of 2.85 indicates that BDMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
- The Altman-Z score of BDMD (2.85) is better than 66.84% of its industry peers.
- A Debt/Equity ratio of 0.56 indicates that BDMD is somewhat dependend on debt financing.
- BDMD's Debt to Equity ratio of 0.56 is on the low side compared to the rest of the industry. BDMD is outperformed by 62.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.85 |
ROIC/WACC3.65
WACC6.64%
2.3 Liquidity
- BDMD has a Current Ratio of 1.71. This is a normal value and indicates that BDMD is financially healthy and should not expect problems in meeting its short term obligations.
- BDMD has a worse Current ratio (1.71) than 70.05% of its industry peers.
- A Quick Ratio of 1.67 indicates that BDMD should not have too much problems paying its short term obligations.
- BDMD's Quick ratio of 1.67 is in line compared to the rest of the industry. BDMD outperforms 44.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.71 | ||
| Quick Ratio | 1.67 |
3. BDMD Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an nice 18.58% over the past year.
- The Revenue has grown by 17.74% in the past year. This is quite good.
EPS 1Y (TTM)18.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-356.32%
Revenue 1Y (TTM)17.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-39.41%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. BDMD Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 3.73, which indicates a rather cheap valuation of BDMD.
- Compared to the rest of the industry, the Price/Earnings ratio of BDMD indicates a rather cheap valuation: BDMD is cheaper than 97.86% of the companies listed in the same industry.
- The average S&P500 Price/Earnings ratio is at 26.64. BDMD is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.73 | ||
| Fwd PE | N/A |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BDMD indicates a rather cheap valuation: BDMD is cheaper than 98.93% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 4.37 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. BDMD Dividend Analysis
5.1 Amount
- BDMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BDMD Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:BDMD (5/1/2026, 8:11:12 PM)
1.79
+0.07 (+4.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)05-15 2025-05-15
Earnings (Next)N/A N/A
Inst Owners1.44%
Inst Owner ChangeN/A
Ins Owners49.82%
Ins Owner Change0%
Market Cap65.75M
Revenue(TTM)37.04M
Net Income(TTM)12.50M
AnalystsN/A
Price TargetN/A
Short Float %2.97%
Short Ratio0.13
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 3.73 | ||
| Fwd PE | N/A | ||
| P/S | 1.78 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.85 | ||
| P/tB | 1.85 | ||
| EV/EBITDA | 4.37 |
EPS(TTM)0.48
EY26.82%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS1.01
BVpS0.97
TBVpS0.97
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.23484 (80.72%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.24% | ||
| ROE | 35.14% | ||
| ROCE | 36.88% | ||
| ROIC | 24.25% | ||
| ROICexc | 25.24% | ||
| ROICexgc | 25.27% | ||
| OM | 41.35% | ||
| PM (TTM) | 33.76% | ||
| GM | 88.17% | ||
| FCFM | N/A |
ROA(3y)11.63%
ROA(5y)N/A
ROE(3y)20.43%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.56 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.2 | ||
| Cap/Depr | 210.97% | ||
| Cap/Sales | 6.52% | ||
| Interest Coverage | 24.84 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.71 | ||
| Quick Ratio | 1.67 | ||
| Altman-Z | 2.85 |
F-Score2
WACC6.64%
ROIC/WACC3.65
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-356.32%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)17.74%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-39.41%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-249.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-143.28%
OCF growth 3YN/A
OCF growth 5YN/A
BAIRD MEDICAL INVESTMENT HOL / BDMD Fundamental Analysis FAQ
What is the ChartMill fundamental rating of BAIRD MEDICAL INVESTMENT HOL (BDMD) stock?
ChartMill assigns a fundamental rating of 3 / 10 to BDMD.
What is the valuation status of BAIRD MEDICAL INVESTMENT HOL (BDMD) stock?
ChartMill assigns a valuation rating of 3 / 10 to BAIRD MEDICAL INVESTMENT HOL (BDMD). This can be considered as Overvalued.
Can you provide the profitability details for BAIRD MEDICAL INVESTMENT HOL?
BAIRD MEDICAL INVESTMENT HOL (BDMD) has a profitability rating of 5 / 10.
Can you provide the financial health for BDMD stock?
The financial health rating of BAIRD MEDICAL INVESTMENT HOL (BDMD) is 3 / 10.